A simple and robust LC–MS/MS method for measuring sirolimus and everolimus in whole blood

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Vezina C, Kudelski A, Sehgal S. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo) 28(10), 721–726 (1975).
  Medline CASGoogle Scholar
• 2 Kirchner G, Meier-Wiedenbach I, Manns M. Clinical pharmacokinetics of everolimus. Clin. Pharmacokinet. 43(2), 83–95 (2004).
  Medline CASGoogle Scholar
• 3 Monchaud C, Marquet P. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I. Clin. Pharmacokinet. 48(7), 419–462 (2009).
  Medline CASGoogle Scholar
• 4 Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5(8), 671–688 (2006).
  Medline CASGoogle Scholar
• 5 Sedrani R, Cottens S, Kallen J, Schuler W. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant. Proc. 30(5), 2192–2194 (1998).
  Medline CASGoogle Scholar
• 6 Neumayer H, Paradis K, Korn A et al. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br. J. Clin. Pharmacol. 48(5), 694–703 (1999).
  Medline CASGoogle Scholar
• 7 Strom T, Haschke M, Zhang Y et al. Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients. Ther. Drug Monit. 29(5), 592–599 (2007).
  Medline CASGoogle Scholar
• 8 Gallant-Haidner H, Trepanier D, Freitag D, Yatscoff R. Pharmacokinetics and metabolism of sirolimus. Ther. Drug Monit. 22(1), 31–35 (2000).
  Medline CASGoogle Scholar
• 9 Kovarik J, Tedesco H, Pascual J et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther. Drug Monit. 26(5), 499–505 (2004).
  Medline CASGoogle Scholar
• 10 Holt D, Denny K, Lee T, Johnston A. Therapeutic monitoring of sirolimus: its contribution to optimal prescription. Transplant. Proc. 35(Suppl. 3), S157–S161 (2003).
  Medline CASGoogle Scholar
• 11 Kahan B, Napoli K, Kelly P et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin. Transplant. 14(2), 97–109 (2000).
  Medline CASGoogle Scholar
• 12 Kelly P, Kahan B. Review: metabolism of immunosuppressant drugs. Curr. Drug Metab. 3(3), 275–287 (2002).
  Medline CASGoogle Scholar
• 13 Johnson-Davis K, De S, Jimenez E, McMillin Ga, De B. Evaluation of the Abbott ARCHITECT i2000 sirolimus assay and comparison with the Abbott IMx sirolimus assay and an established liquid chromatography-tandem mass spectrometry method. Ther. Drug Monit. 33(4), 453–459 (2011). •• Two commercial immunoassays showed positive bias in sirolimus measurement relative to an LC–MS/MS method.
  Medline CASGoogle Scholar
• 14 Dasgupta A, Davis B, Chow L. Evaluation of QMS everolimus assay using Hitachi 917 Analyzer: comparison with liquid chromatography/mass spectrometry. Ther. Drug Monit. 33(2), 149–154 (2011).
  Medline CASGoogle Scholar
• 15 Yang Z, Wang S. Recent development in application of high performance liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressants. J. Immunol. Methods 336(2), 98–103 (2008). •• Recent developments in LC–MS/MS analysis of immunosuppressants are reviewed.
  Medline CASGoogle Scholar
• 16 Bogusz M, Enazi E, Hassan H, Abdel-Jawaad J, Ruwaily , J, Tufail M. Simultaneous LC–MS-MS determination of cyclosporine A, tacrolimus, and sirolimus in whole blood as well as mycophenolic acid in plasma using common pretreatment procedure. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 850(1–2), 471–480 (2007).
  Medline CASGoogle Scholar
• 17 Heideloff C, Payto D, Wang S. Comparison of a stable isotope-labeled and an analog internal standard for the quantification of everolimus by a liquid chromatography-tandem mass spectrometry method. Ther. Drug Monit. 35(2), 246–250 (2013).
  Medline CASGoogle Scholar
• 18 Korecka M, Solari S, Shaw L. Sensitive, high throughput HPLC–MS/MS method with on-line sample clean-up for everolimus measurement. Ther. Drug Monit. 28(4), 484–490 (2006).
  Medline CASGoogle Scholar
• 19 Korecka M, Patel R, Shaw L. Evaluation of performance of new, isotopically labeled internal standard ([13c2d4]RAD001) for everolimus using a novel high-performance liquid chromatography tandem mass spectrometry method. Ther. Drug Monit. 33(4), 460–463 (2011).
  Medline CASGoogle Scholar
• 20 Mueller D, Rentsch K. Sensitive quantification of sirolimus and everolimus by LC–MS/MS with online sample cleanup. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 878(13–14), 1007–1012 (2010).
  Medline CASGoogle Scholar
• 21 Meinitzer A, Gartner G, Pilz S, Stettin M. Ultra fast liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of cyclosporin A, tacrolimus, sirolimus, and everolimus in whole blood using deuterated internal standards for cyclosporin A and everolimus. Ther. Drug Monit. 32(1), 61–66 (2010).
  Medline CASGoogle Scholar
• 22 Taylor P, Franklin M, Graham K, Pillans P. A HPLC-mass spectrometric method suitable for the therapeutic drug monitoring of everolimus. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 848(2), 208–214 (2007).
  Medline CASGoogle Scholar
• 23 Mano N, Sato M, Nozawa M et al. An accurate quantitative LC/ESI-MS/MS method for sirolimus in human whole blood. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 879(13–14), 987–992 (2011).
  Medline CASGoogle Scholar
• 24 Wang S, Miller A. A rapid liquid chromatography-tandem mass spectrometry analysis of whole blood sirolimus using turbulent flow technology for online extraction. Clin. Chem. Lab. Med. 46(11), 1631–1634 (2008). • This is our original LC–MS/MS method for measuring sirolimus with the use of a column heater.
  Medline CASGoogle Scholar
• 25 Yuan C, Heideloff C, Kozak M, Wang S. Simultaneous quantification of 19 drugs/metabolites in urine important for pain management by liquid chromatography-tandem mass spectrometry. Clin. Chem. Lab. Med. 50(1), 95–103 (2012).
  CASGoogle Scholar
• 26 Bonfiglio R, King R, Olah T, Merkle K. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun. Mass Spectrom. 13(12), 1175–1185 (1999).
  Medline CASGoogle Scholar
• 27 Yuan C, Kosewick J, He X, Kozak M, Wang S. Sensitive measurement of serum 1alpha,25-dihydroxyvitamin D by liquid chromatography/tandem mass spectrometry after removing interference with immunoaffinity extraction. Rapid Commun. Mass Spectrom. 25(9), 1241–1249 (2011).
  Medline CASGoogle Scholar
• 28 Capone D, Gentile A, Polichetti G et al. Stability of sirolimus and everolimus measured by immunoassay techniques in whole blood samples from kidney transplant patients. Int. J. Immunopathol. Pharmacol. 21(2), 297–307 (2008). • Stability of sirolimus and everolimus was investigated at different temperatures.
  Medline CASGoogle Scholar
• 29 Salm P, Tresillian M, Taylor P, Pillans P. Stability of sirolimus (rapamycin) in whole blood. Ther. Drug Monit. 22(4), 423–426 (2000).
  Medline CASGoogle Scholar
• 30 Mano N, Nozawa M, Sato M et al. Identification and elimination of ion suppression in the quantitative analysis of sirolimus in human blood by LC/ESI-MS/MS. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 879(13–14), 968–974 (2011). • Matrix effect (ion supression) in the LC–MS/MS analysis of sirolimus was systematically investigated, and a way of reducing matrix effect was demonstrated.
  Medline CASGoogle Scholar
• 31 Ivanova M, Artusi C, Polo G, Zaninotto M, Plebani M. High-throughput LC–MS/MS method for monitoring sirolimus and everolimus in the routine clinical laboratory. Clin. Chem. Lab. Med. 49(7), 1151–1158 (2011). • A very fast (3.5 min) and sensitive (lower limit of quantification: 0.2 ng/ml) LC–MS/MS method is presented for measuring sirolimus and everolimus.
  Medline CASGoogle Scholar